GlassScriptPhysician profile
Douglas J Vanputten
NPI 1851378558
$87,932.82
in general payments reported to CMS, 2019-2025
14 companies · $33K in 2025
The $33K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.98 · 2021: $531 · 2022: $8,548 · 2023: $22K · 2024: $24K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Honoraria: $19K · Travel and Lodging: $9,198 · Food and Beverage: $5,256 · Consulting Fee: $5,100 · Education: $25.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,375.00 |
| Honoraria | $18,887.50 |
| Travel and Lodging | $9,197.68 |
| Food and Beverage | $5,256.42 |
| Consulting Fee | $5,100.00 |
| Education | $25.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $56,733.30 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $30,325.59 | 2021-2023 | Tepezza |
| Alcon Vision LLC | $145.06 | 2022 | |
| Mallinckrodt Hospital Products INC. | $128.46 | 2020-2021 | |
| Glaxosmithkline, LLC. | $125.00 | 2023 | Benlysta |
| Argenx US, INC. | $115.66 | 2024 | |
| Dompe US, INC. | $110.78 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $80.00 | 2022-2024 | Eylea, Eylea Hd |
| Ani Pharmaceuticals, INC. | $61.12 | 2025 | Purified Cortrophin Gel |
| Johnson & Johnson Surgical Vision, INC. | $35.55 | 2025 | Tecnis Simplicity |
| Aerie Pharmaceuticals, INC. | $24.10 | 2021 | |
| Apellis Pharmaceuticals, INC. | $20.24 | 2025 | Syfovre |
| Ucb, INC. | $15.00 | 2025 | Rystiggo |
| Allergan, INC. | $12.96 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Vanputten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.